Clinical impact of post-progression survival for overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

  • Norimitsu Kasahara Shizuoka Cancer Center
  • Hisao Imai Gunma University Graduate School of Medicine
  • Kyoichi Kaira Gunma University Graduate School of Medicine
  • Keita Mori Shizuoka Cancer Center
  • Kazushige Wakuda Shizuoka Cancer Center
  • Akira Ono Shizuoka Cancer Center
  • Tetsuhiko Taira Shizuoka Cancer Center
  • Hirotsugu Kenmotsu Shizuoka Cancer Center
  • Hideyuki Harada Shizuoka Cancer Center
  • Tateaki Naito Shizuoka Cancer Center
  • Haruyasu Murakami Shizuoka Cancer Center
  • Masahiro Endo Shizuoka Cancer Center
  • Takashi Nakajima Shizuoka Cancer Center
  • Masanobu Yamada Gunma University Graduate School of Medicine
  • Toshiaki Takahashi Shizuoka Cancer Center

Abstract

Objectives: The effects of first-line chemoradiotherapy on overall survival (OS) may be confounded by subsequent lines of therapy in patients with limited-stage disease small cell lung cancer (LD-SCLC). Therefore, we aimed to determine the relationships between progression-free survival (PFS) or post-progression survival (PPS) and OS after first-line chemoradiotherapy in LD-SCLC.

Methods: We retrospectively analyzed 71 LD-SCLC patients who received first-line chemoradiotherapy and had disease recurrence between September 2002 and March 2013 at Shizuoka Cancer Center (Shizuoka, Japan). We determined the correlation between PFS and OS between PPS and OS at the individual level. In addition, we performed univariate and multivariate analyses to identify significant prognostic factors of PPS.

Results: OS is more strongly correlated with PPS (Spearman's r=0.86, R2=0.72, p<0.05) than PFS (Spearman's r=0.46, R2=0.38, p<0.05). In addition, the response to second-line treatments, the presence of distant metastases at recurrence and the number of additional regimens after first-line chemoradiotherapy were significant independent prognostic factors for PPS.

Conclusions: PPS has more impact for OS than PFS in LD-SCLC patients. Moreover, treatments administered after first-line chemoradiotherapy may affect their OS. However, larger multicenter studies are needed to validate these conclusions.

Author Biographies

Norimitsu Kasahara, Shizuoka Cancer Center
Hisao Imai, Gunma University Graduate School of Medicine
Kyoichi Kaira, Gunma University Graduate School of Medicine
Keita Mori, Shizuoka Cancer Center
Kazushige Wakuda, Shizuoka Cancer Center
Akira Ono, Shizuoka Cancer Center
Tetsuhiko Taira, Shizuoka Cancer Center
Hirotsugu Kenmotsu, Shizuoka Cancer Center
Hideyuki Harada, Shizuoka Cancer Center
Tateaki Naito, Shizuoka Cancer Center
Haruyasu Murakami, Shizuoka Cancer Center
Masahiro Endo, Shizuoka Cancer Center
Takashi Nakajima, Shizuoka Cancer Center
Masanobu Yamada, Gunma University Graduate School of Medicine
Toshiaki Takahashi, Shizuoka Cancer Center
Published
2016-01-11
How to Cite
Kasahara, N., Imai, H., Kaira, K., Mori, K., Wakuda, K., Ono, A., Taira, T., Kenmotsu, H., Harada, H., Naito, T., Murakami, H., Endo, M., Nakajima, T., Yamada, M., & Takahashi, T. (2016). Clinical impact of post-progression survival for overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy. Radiology and Oncology, 49(4). Retrieved from https://radioloncol.com/index.php/ro/article/view/2332
Section
Clinical oncology